European generic drug manufacturers are scrambling to reassess supply contracts and procurement strategies on Sunday after BASF Pharma Solutions confirmed an immediate price increase of up to 20% on excipients and active pharmaceutical ingredients (APIs), a move that industry analysts say will ripple through medicine supply chains across the continent within weeks.
The price hike, announced by BASF late Friday, takes effect immediately with no transition period, catching several mid-sized generics producers off-guard. Companies including Stada Arzneimittel, Sandoz, and smaller central European contract manufacturers are understood to be convening emergency procurement reviews this weekend to assess exposure and identify alternative suppliers in India and China before the cost increases fully embed into their cost structures.
Industry body the European Fine Chemicals Group (EFCG) is expected to issue a formal statement Sunday, calling on BASF to provide a phased implementation schedule and urging European regulators to monitor the situation for potential downstream impact on medicine affordability. Procurement executives at several firms noted that BASF's position as a dominant supplier of specialty excipients leaves limited short-term substitution options, particularly for complex formulations such as modified-release tablets and injectables.
The timing is particularly sensitive. Europe's pharmaceutical supply chain has already been under strain from tariff uncertainty following the Trump administration's 'Liberation Day' measures, and a cost shock of this magnitude from a key upstream supplier is expected to accelerate conversations in Brussels about strategic raw material stockpiling and supplier diversification. The European Medicines Agency has previously flagged API concentration risk as a systemic vulnerability.
Analysts at Jefferies noted in a weekend research note that the BASF increase could add between 3% and 8% to the cost of goods for affected manufacturers depending on formulation complexity, squeezing margins at a moment when reimbursement pricing in Germany and France remains tightly controlled. Several smaller generics firms with less diversified supplier bases may face difficult choices between absorbing the cost or seeking price renegotiations with national health authorities — a process that typically takes months.